25.55  -0.44 (-1.69%)		04-24 11:16
Open: 26.04 High: 26.19 Volume: 348,367		Pre. Close: 25.99 Low: 25.19 Market Cap: 3,146(M)

Short term
Mid term
Targets	6-month :	33.03	1-year :	38.58
Resists	First :	28.28	Second :	33.03
Pivot price	23.96
Supports	First :	23.07	Second :	19.86
MAs	MA(5) :	25.4	MA(20) :	23.63
	MA(100) :	21.61	MA(250) :	11.26
MACD	MACD :	0.2	Signal :	-0.2
%K %D	K(14,3) :	75.2	D(3) :	81
RSI	RSI(14): 55
52-week	High :	30.6	Low :	2.75

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ALMS ] has closed below upper band by 22.6%. Bollinger Bands are 25.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	28.32 - 28.44	28.44 - 28.55
Low:	25.58 - 25.69	25.69 - 25.8
Close:	25.81 - 26	26 - 26.2

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.

Fri, 03 Apr 2026
Foresite funds realign Alumis (ALMS) stakes via in-kind distributions - Stock Titan

Fri, 03 Apr 2026
Tananbaum-led funds update Alumis (ALMS) ownership and 13D stake - Stock Titan

Fri, 03 Apr 2026
Foresite entities move ALUMIS (ALMS) shares in pro rata in-kind distributions - Stock Titan

Fri, 03 Apr 2026
Alumis (ALMS) insider-linked entities shift 4.1M shares via in-kind distributions - Stock Titan

Mon, 12 Jan 2026
Foresite Labs buys Alumis (ALMS) shares worth $7 million - Investing.com

Fri, 09 Jan 2026
Alumis Inc. Announces Closing of $345.1 Million Upsized Public Offering of Common Stock - Quiver Quantitative

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	123 (M)
Held by Insiders	8.499e+007 (%)
Held by Institutions	0.6 (%)
Shares Short	7,950 (K)
Shares Short P.Month	0 (K)

EPS	-4.3841e+008
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-5 %
Return on Assets (ttm)	67.1 %
Return on Equity (ttm)	-73.4 %
Qtrly Rev. Growth	2.405e+007 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	-2.9 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-370 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	1.123e+007
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.